A5112217748- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Adrenal and Paraganglionic Tumors
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Medical Imaging and Pathology Studies
- Prostate Cancer Diagnosis and Treatment
- Hormonal Regulation and Hypertension
- Neuropeptides and Animal Physiology
- Cancer Immunotherapy and Biomarkers
- Pituitary Gland Disorders and Treatments
- Mass Spectrometry Techniques and Applications
- Thyroid Cancer Diagnosis and Treatment
- Radioactive Decay and Measurement Techniques
- Face and Expression Recognition
- Infant Health and Development
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Cardiovascular Issues in Pregnancy
- Myasthenia Gravis and Thymoma
VIT-AP University
2025
SRM University
2025
Gandhi Medical College & Hospital
2022
Maastricht University
2019-2021
Zentralklinik Bad Berka
2015-2021
Gandhi Medical College
2020
European Neuroendocrine Tumor Society
2017-2019
University of Buckingham
2018
Canberra Hospital
2008
Hammersmith Hospital
2006-2007
The objective of this study was to analyze the safety and efficacy <sup>177</sup>Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand <sup>177</sup>Lu-DOTAGA-(I-y)fk(Sub-KuE) (<sup>177</sup>Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). <b>Methods:</b> Fifty-six mCRPC underwent PSMA radioligand therapy (RLT) <sup>177</sup>Lu-PSMA....
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 the conjugate FAP-binding peptide, which can be labeled with radionuclides theranostic applications. We present first-in-human results using <sup>177</sup>Lu-FAP-2286 peptide-targeted radionuclide (PTRT). <b>Methods:</b> PTRT was performed in 11 patients advanced adenocarcinomas pancreas, breast, rectum ovary after prior confirmation uptake on...
We recently introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist <sup>68</sup>Ga-SB3 (<sup>68</sup>Ga-DOTA-<i>p</i>-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt), showing excellent tumor localizing efficacy in animal models and patients. By replacement of C-terminal Leu<sup>13</sup>-Met<sup>14</sup>-NH<sub>2</sub> dipeptide SB3 by Sta<sup>13</sup>-Leu<sup>14</sup>-NH<sub>2</sub>, novel GRPR NeoBOMB1 was generated labeled with different...
Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study.In our center, 2294 were screened between 2004 2014 by 68Ga (SSTR) PET/CT. Intention to treat analysis included 1048 patients, who received at least one cycle 90Yttrium or 177Lutetium-based PRRT. Progression free survival was determined SSTR-PET/CT EORTC response criteria. Adverse events CTCAE...
177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177Lu-PRLT earlier later phases mCRPC grouped by previous taxane chemotherapy. Methods: A analysis was performed on 167 patients with who underwent between March 2013 December 2016. Patients were classified as either chemotherapy...
To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index greater than 20%. The purpose this study was to analyze the long-term outcome, efficacy, and safety PRRT in patients somatostatin (SSTR)-expressing G3 NENs. Methods: A total 69 (41 men; age, 28-81 y) received 177Lu- or 90Y-labeled analogs (DOTATATE DOTATOC). Twenty-two had radiosensitizing chemotherapy. Kaplan-Meier...
<sup>161</sup>Tb has decay properties similar to those of <sup>177</sup>Lu but, additionally, emits a substantial number conversion and Auger electrons. The aim this study was apply in clinical setting investigate the feasibility visualizing physiologic tumor biodistributions <sup>161</sup>Tb-DOTATOC. <b>Methods:</b><sup>161</sup>Tb shipped from Paul Scherrer Institute, Villigen-PSI, Switzerland, Zentralklinik Bad Berka, Germany, where it used for radiolabeling DOTATOC. In 2 separate...
Indian mythology is a treasure trove of divine tales, yet gap in understanding still exists between foreign tourists and the rich cultural heritage deities. To address problem, this paper presents deep learning-driven mobile application named "MythicVision" designed to help better understand India's by recognizing interpreting images mythological At first, four state-of-the-art models have been trained evaluated on custom in-house dataset consists 10,970 various deities sourced from both...
Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which still one of the deadliest cancers, with a very poor prognosis. Eligible patients were offered salvage radiopharmaceutical therapy novel NTR1 antagonist 177Lu-3BP-227. Methods: Six confirmed adenocarcinoma who had exhausted all other treatment options received 177Lu-3BP-227 for evaluation expression vivo. Three activities 5.1-7.5 GBq. Results: Administration was well tolerated by patients. The kidneys...
The existence of theragnostic pairs radionuclides allows the preparation radiopharmaceuticals for diagnostic and therapeutic purposes.
For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152Tb and 155Tb are the identified PET or SPECT imaging, while 149Tb 161Tb suitable decay characteristics α- combined β−/Auger-e−-therapy, respectively. In present study, of 152Tb, combination with PSMA-617 imaging prostate-specific membrane antigen (PSMA)-positive prostate cancer, was demonstrated preclinical setting patient metastatic castration-resistant cancer...
The objective of this retrospective study was to determine the role <sup>18</sup>F-FDG PET/CT in a large cohort 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated peptide receptor radionuclide therapy (PRRT) long-term follow-up. <b>Methods:</b> <sup>177</sup>Lu- or <sup>90</sup>Y-DOTATOC/DOTATATE PRRT between February 2002 and July 2018. All subjects received both <sup>68</sup>Ga-DOTATOC/TATE/NOC before treatment followed 3–189 mo. Kaplan–Meier analysis, log-rank...
44Sc is a promising positron emission tomography (PET) radionuclide (T1/2 = 4.04 hours, Eβ+average 632 keV) and can be made available, using cyclotron production route, in substantial quantities as highly pure product. Herein, the authors report on first-in-human PET/CT study 44Sc-DOTATOC prepared with cyclotron-produced 44Sc. The of was carried out through 44Ca(p,n)44Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation, shipped to Zentralklinik Bad Berka, Germany,...
Aim: The prostate-specific membrane antigen (PSMA) is a cell surface protein, which overexpressed in nearly all cases of prostate cancer (PCa). PET imaging with 68Ga-PSMA-HBED-CC has recently found widespread application the diagnosis recurrent PCa. In this study, diagnostic potential 64Cu-labeled PSMA ligand (PSMA-617) patients PCa been investigated. Materials and Methods: study was conducted simultaneously at two nuclear medicine centers, Austria (Vienna, Center 1) Germany (Bad Berka, 2)....
// Finn Edler von Eyben 1, * , Aviral Singh 2, Jingjing Zhang 2 Karin Nipsch Danielle Meyrick 3 Nat Lenzo 3, 4 Kalevi Kairemo 5 Timo Joensuu Irene Virgolini 6 Cigdem Soydal 7 Harshad R. Kulkarni # and Richard Paul Baum 1 Center of Tobacco Control Research, Odense, Denmark Theranostics for Molecular Radiotherapy Imaging, Zentralklinik Bad Berka, Germany GenesisCare Oncology, Theranostics, East Freemantle, Australia School Medicine Pharmacology, University Western Australia, Nedlands, Docrates...
In molecular radiotherapy with 177Lu-labeled prostate specific membrane antigen (PSMA) peptides, kidney and/or salivary glands doses limit the activity which can be administered. The aim of this work was to investigate effect ligand amount and injected on tumor-to-normal tissue biologically effective dose (BED) ratio for PSMA peptides. For retrospective study, a recently developed physiologically based pharmacokinetic model adapted targeting General physiological parameters were taken from...